Arcutis Biotherapeutics Inc Stock News

Shares of dermatology biopharma Arcutis Biotherapeutics, Inc. fell 16% the day after receiving its first FDA approval for ZORYVE (roflumilast) in the treatment of plaque psoriasis. The market seemed t

Zoryve (roflumilast cream) was approved by the FDA to treat psoriasis on August 1, 2022. The phase 3 STRATUM trial met the endpoint and an NDA will be submitted to FDA for roflumilast foam to be appro

WESTLAKE VILLAGE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-de

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and AVEO Pharmaceuticals (AVEO) have performed compared to their sector so far this year.

WESTLAKE VILLAGE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), an early-stage commercial biopharmaceutical company focused on developing meaningful innovat

WESTLAKE VILLAGE, Calif., May 05, 2022 (GLOBE NEWSWIRE) --  Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in imm

Phase 3 data from the DERMIS Phase 3 trials demonstrated an excellent efficacy profile for roflumilast in psoriasis.

WESTLAKE VILLAGE, Calif., March 25, 2022 (GLOBE NEWSWIRE) --  Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in i

WESTLAKE VILLAGE, Calif., March 25, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in imm

WESTLAKE VILLAGE, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in imm

WESTLAKE VILLAGE, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in imm

WESTLAKE VILLAGE, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in an upcoming investor conference.

WESTLAKE VILLAGE, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immu

Arcutis Biotherapeutics press release (ARQT): Q4 GAAP EPS of -$1.42 beats by $0.18.Strong financial position with more than $385M in cash, cash equivalents, and marketable securities.

WESTLAKE VILLAGE, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immun